MyOme is a clinical whole genome analysis platform company that provides clinical reports to help families and health systems understand inherited disease risk. The company is CLIA-certified and translates whole-genome sequencing into clinical reports. MyOme intends to use its recent funding to begin commercialization of its platform technology and clinical reporting services to health systems. Leadership includes CEO Premal Shah, PhD, and co-founder and chairman Matthew Rabinowitz, PhD. The company is based in Menlo Park, California. As of the Series B, MyOme had raised over $36M in total.

Total raised

$23M

Funding rounds

1

Latest round

Series B

Latest activity

Jun 2022